ATI-2138 is under clinical development by Aclaris Therapeutics and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ATI-2138’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ATI-2138 overview

ATI-2138 is under development for the treatment of atopic dermatitis, psoriasis, inflammatory dermatoses, arthritis, inflammatory bowel disease and ulcerative colitis. It is administered through oral route. The drug candidate is an ITK/TXK/JAK3 inhibitor. It is developed based on KINect, drug discovery platform. 

Aclaris Therapeutics overview

Aclaris Therapeutics is a biopharmaceutical company. It identifies, develops and commercializes small molecule therapies for immuno-inflammatory conditions. The company product, ESKATA is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). Its pipeline products include A-101, ATI-1777-oral JAK 1/3 inhibitor, ATI-501, ATI-450-oral MK2 pathway inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.

For a complete picture of ATI-2138’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.